SYNERGY Research

End-to-End Pharmacovigilance Service Provider
Mahwah, NJ
Washington, DC
Stroudsburg, PA
Honolulu, HI


Pharmacovigilance Solutions
  • Serious Adverse Event (SAE) /SUSARs management

  • Adverse Event (AE) data intake

  • Secure, accurate, and timely case entry and evaluation into validated safety database

  • Coding (MedDRA, WHO Drug)

  • Safety database

  • Annual safety reports and DSURs

  • Medical Review

  • Patient Event narrative

  • Regulatory Support and Intelligence

  • Literature Search Services

  • Report via Eudravigilance

  • Safety Medical Writing

  • Medical Information Support

Coronavirus disease (COVID-2019) R&D

On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. Read more...


Biopharmaceutical industry leads the way in making diagnostics kits, developing new vaccines and treatments to contain COVID-19

Nearly 80 clinical trials for experimental new treatments and vaccines in development for coronaviruses including COVID-19, Novel Coronavirus Pneumonia, SARS and MERS.